Lantern Pharma Subsidiary Starlight Therapeutics Names New Chief Medical Officer to Oversee Clinical Trials

Starlight Therapeutics is focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.

Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.

Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.

In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG).

“Starlight Therapeutics and Lantern Pharma are poised to transform oncology with AI-enabled drug development aimed at providing advanced precision therapeutics for cancers in areas of severely unmet need, such as multiple types of pediatric and adult brain cancers, for which there is currently no cure,” Panna Sharma, CEO and president of Lantern Pharma, said in a statement.

Sharma said Chamberlain’s expertise in neuro-oncology and therapeutic development will be “invaluable” to the further development of treatments in the pipeline, as well as the the discovery and development of treatments needed by cancer patients.

Starlight said that in his new role, Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio.

Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric neurology and neuro-oncology.

The company said his experience before joining Starlight included serving as the co-director of the neuro-oncology programs at four NCI designated cancer centers— Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of South Florida, and Fred Hutchinson Cancer Center at the University of Washington.

Chamberlain also served as medical director for Cascadian Therapeutics, Seattle Genetics, SystImmune, Angiochem, and Pionyr Immunotherapeutics. He has published more than 300 neurology-focused papers in peer-reviewed journals.

“Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001” for CNS indications), to target tumors in the brain,” Chamberlain said. “We are now preparing for two recurrent glioblastoma studies as part of a larger planned expansion study to assess STAR-001 in subjects who have failed standard-of-care temozolomide and involved field radiotherapy.”

Chamberlain noted that the development of STAR-001 for use in brain tumors used Lantern’s RADR® platform in modeling and preclinical experimentation in multiple in-vitro and in-vivo models.

“I’m looking forward to working alongside the talented researchers and experts at Lantern and its collaborators at Starlight who have already done so much to advance these treatments. I look forward to working together with our collaborators and clinicians to bring these and many more innovative neuro-oncology treatments to the patients who need them,” he said.

Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • "There are over 10,000 rare diseases that affect millions of people worldwide, and most of them are genetic," notes UT Southwestern's Steven Gray (above, with Susan Iannaccone, M.D.). Testing on a total of eight genetic diseases has been approved for funding by the Bespoke Gene Therapy Consortium and other organizations.

  • Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members. Lantern Pharma is a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development. The startup said the expansion of the clinical development team will continue to advance the Harmonic trial, a Phase 2 trial for never smokers with NSCLC, as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184…

  • The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.

  • The Dallas-based customer experience hub of the Advanced Research Projects Agency for Health had its official launch yesterday at Pegasus Park. The hub's first mission: making it easier for Americans from across the country to take part in clinical trials, through the Advancing Clinical Trial Readiness Initiative.

  • Dallas' Secretome Therapeutics Appoints Board Director, Assembles Clinical Advisory Board

    Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure. “I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to…